Yabao Pharmaceuticals and University of South Australia announce joint Drug Discovery Laboratory

By / 7th of September, 2015

A LEADING Chinese pharmaceutical company has teamed up with an Australian university to develop new cancer treatments.

Yabao Pharmaceutical Co, Inc. and the University of South will collaborate to develop new treatments for cancer.

Under the terms of the agreement, the University of South Australia will identify drug candidates in a co-funded laboratory led by the university’s Professor Shudong Wang.

Yabao Pharmaceuticals will fund the drug discovery and development in exchange for the exclusive right to develop and commercialise the drug candidates in China.

The University of South Australia will retain rights in all other markets.

Yabao Pharmaceutical’s president of R&D, Dr Peng Wang, says Yabao seeks to build relationships with organisations that have innovative programs that complement the company’s development and commercial capabilities.

“We are thrilled to have the opportunity to work with the University of South Australia’s highly regarded scientists and laboratories to jointly find a way to develop important new treatments for cancer patients.”

Vice Chancellor and President of the University of South Australia, Professor David Lloyd says there are no international barriers to great research and development.

“We are thrilled to have forged such a strong collaboration in China that will enhance the development of new therapies for cancer, a disease that continues to present one of our greatest global challenges,” Prof Lloyd says.

“We look forward to working closely with Yabao Pharmaceuticals with the shared goal of developing novel anti-cancer agents to patients in China and globally.”

Head of Centre for Drug Discovery and Development at the University of South Australia Professor Shudong Wang says she is looking forward to a productive collaboration with Yabao, which brings a strong commitment to the Centre’s drug discovery program.

“The financial resources resulting from this agreement will help to rapidly advance our drug discovery towards clinical development, a goal we all share.”

Contact:

University of South Australia
Michele Nardelli, +61 418823673
michele.nardelli@unisa.edu.au

Yabao
Ms. Weina Liu, +86-10-5808-6285
liuweina@yabaoyaoye.com